|
|
Article: Using litigation to regulate drug prices: the assault on AWP.(Average wholesale price for pharmaceutical products)(Government Activity)
- Article from:
- Medical Marketing & Media
- Article date:
- June 1, 2002
- Author:
CopyrightCOPYRIGHT 2002 Haymarket Media, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
A "sleeper" issue hangs over the Rx industry. The TAP/Lupron settlement with the government opened up the contentious subject of "average wholesale price" (AWP) -- the actual cost of Medicare Part B drugs to providers and what they charge Medicare and other insurance carriers. With lawsuits on the horizon, one article, authored by knowledgeable beltway attorneys, presents a suggested industry defense to these suits, and, in a companion piece, MM&M comments on the charges brought in a representative legal action.
For the past several years, federal healthcare agencies have been engaged in a smoldering dispute over whether the average wholesale price (AWP) or ...